What happened with ERAS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Erasca is testing medicines intended to block the signaling network known as RAS/MAPK that drives certain cancers. Its two clinical programs, ERAS-0015 and ERAS-4001, are in Phase 1 trials; other candidates remain in preclinical research or discovery. It has no approved products and has generated no revenue, so capital raised from investors, rather than customer payments, funds its work.
Erasca licensed ERAS-0015 from Joyo and ERAS-4001 from Medshine and now holds worldwide rights to both. These agreements require milestone payments and royalties on eventual sales. The company also relies on outside manufacturers for drug supplies and needs additional funding to continue development.
If its medicines win regulatory approval, Erasca plans to sell them itself in the United States and potentially Europe, while likely using commercialization partners elsewhere. It has not yet built a sales or distribution organization. Product revenue depends first on demonstrating safety and effectiveness and obtaining approval, then on doctors and patients adopting the medicines and governments and insurers providing coverage and adequate reimbursement.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Erasca’s prospects hinge on clinical success of its RAS drugs and keeping the core intellectual-property licenses from Joyo and Medshine.
Revolution Medicines competes with Erasca to develop drugs for RAS-driven cancers, so better results or earlier approval could narrow Erasca’s opportunity. Watch clinical results for daraxonrasib, which blocks active RAS, against Erasca’s pan-RAS and pan-KRAS programs.
BridgeBio Oncology Therapeutics competes with Erasca in developing RAS-focused cancer drugs; neither this rivalry nor BBOT’s opportunity yet rests on approved BBOT products. Its clinical results and work combining inhibitors in KRAS-mutant tumors are the developments to watch.
Adlai Nortye’s AN9025 directly competes with Erasca’s ERAS-0015 to treat cancers by blocking a broad range of RAS proteins. Watch Phase I results for this oral inhibitor of active RAS; its reported potency advantage comes from preclinical models, not demonstrated patient outcomes.
Immuneering offers a different way to treat MAPK-driven tumors from Erasca’s RAS inhibitors, using drugs that block MEK in the same signaling pathway. Watch atebimetinib’s efficacy and tolerability in cancers such as pancreatic cancer: its intended durability and tolerability advantages remain goals, not established outcomes.
Verastem’s marketed pathway-targeting combination gives Erasca a real-world benchmark for an alternative to RAS-focused treatment. Watch U.S. sales of AVMAPKI FAKZYNJA CO-PACK for adults with KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy; net product revenue was $30.9 million in the first seven full launch months of 2025.
Tango Therapeutics depends on Erasca supplying its pan-RAS molecular glue for their planned combination study with Tango’s vopimetostat, a cancer drug designed for tumors with MTAP deletion. Watch whether the combination establishes safety, efficacy and each drug’s contribution; failure to do so could delay development or require another treatment partner.
Amgen’s LUMAKRAS is an established treatment benchmark for Erasca’s broader KRAS candidates: it blocks KRAS G12C and is approved for that mutation in non-small cell lung cancer. Its efficacy, safety and use show what Erasca must measure against, while Amgen already earns medicine-sales revenue from wholesalers and healthcare providers.
Bristol Myers Squibb’s marketed KRAZATI sets a clinical and commercial benchmark for Erasca’s broader KRAS inhibitors, but targets the specific G12C mutation. Watch KRAZATI’s efficacy, safety and adoption rather than treating its narrower mutation coverage as equivalent to Erasca’s pan-KRAS approach.
Silexion Therapeutics competes with Erasca by trying to stop mutant KRAS protein from being made, using small interfering RNA rather than blocking the protein itself. Watch SIL204’s development for unresectable, locally advanced pancreatic cancer with KRAS G12D/V mutations, where its planned regimen combines tumor and subcutaneous dosing with standard chemotherapy.
BlossomHill Therapeutics is pursuing the same broad-KRAS cancer-treatment opportunity as Erasca’s ERAS-4001, but its BH-501284 remains preclinical while ERAS-4001 is in clinical development. Watch BH-501284’s development progress, rather than commercial sales: BlossomHill has no history of selling products.
Elicio Therapeutics shares Erasca’s exposure to progress in KRAS-driven cancers, but develops cancer vaccines rather than RAS-blocking drugs. Watch the Phase 2 study of ELI-002 7P in mutant-KRAS-driven pancreatic ductal adenocarcinoma as evidence from a different treatment approach, not as proof that Erasca’s inhibitors work.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report will show whether KRAZATI, its drug for KRAS G12C, continues to gain use, providing a clinical and commercial benchmark for Erasca’s broader RAS drugs.
Read changes in KRAZATI’s use or sales alongside Bristol Myers Squibb’s disclosures about its efficacy and safety. Rising use with evidence that continues to support the drug would show a clinical and commercial foothold for KRAS G12C treatment and strengthen the benchmark facing Erasca’s related drugs; weaker use or safety concerns would soften that benchmark, but would not prove Erasca’s drugs work.
Tango Therapeutics, Inc. earningsTNGX
If Tango Therapeutics’ report updates its planned study with Erasca-supplied ERAS-0015, it will show whether the combination can advance safely and with evidence of efficacy.
Watch for updates on Tango’s planned study combining ERAS-0015 with its vopimetostat, including safety, efficacy and evidence of each drug’s contribution. If the combination advances safely and shows efficacy, ERAS-0015 has a viable development path with this partner; safety problems, unclear results or uncertainty about each drug’s contribution could delay the study or require another treatment partner.
Revolution Medicines, Inc. earningsRVMD
Revolution Medicines’ report will show daraxonrasib’s clinical progress, a competitive signal for Erasca’s effort to treat RAS-driven cancers.
Watch daraxonrasib’s clinical results and development progress. It blocks active RAS, a different approach from Erasca’s pan-RAS and pan-KRAS programs. Strong results or faster progress could let Revolution Medicines compete for similar patients sooner, raising the bar for Erasca; weak results or delays would ease near-term pressure, but would not prove Erasca’s drugs work.
Erasca, Inc. earningsThis company
Erasca’s report will show whether spending to advance ERAS-0015 and ERAS-4001 is bringing clinical progress without cash use outpacing its funding.
Read research and development spending alongside cash used in operations, then compare both with progress in ERAS-0015 and ERAS-4001 and the cash and marketable securities on hand. Progress with contained cash use would show that funding is moving the pipeline forward; rising cash use without corresponding progress would leave less time to develop the drugs before Erasca needs to raise more money.
